Lauren Wilson1, Michael Pawlita2, Phillip E Castle3, Tim Waterboer2, Vikrant Sahasrabuddhe4, Patti E Gravitt5, Mark Schiffman4, Nicolas Wentzensen4. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda Epidemiology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina. 2. German Cancer Research Center, Heidelberg, Germany. 3. Global Cancer Initiative, Chestertown. 4. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda. 5. Department of Epidemiology Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, Maryland.
Abstract
BACKGROUND: Natural human papillomavirus (HPV) antibody titers have shown protection against subsequent HPV infection, but previous studies were restricted to few HPV genotypes. We examined the association of naturally occurring antibodies against 8 carcinogenic HPV types with subsequent infections. METHODS: A total of 2302 women enrolled in the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study provided blood samples at baseline. Serum samples were tested for antibodies against 8 carcinogenic HPV genotypes (16, 18, 31, 33, 35, 45, 52, and 58) using a multiplex serology assay. We analyzed the relationship between HPV antibodies and HPV infection during 2 years of follow-up among women negative for the specific HPV type at baseline. RESULTS: Baseline seroprevalence for HPV16 L1 was associated with decreased risk of DNA positivity for HPV16 (odds ratio, 0.39 [95% confidence interval, .18-.86]) at ≥2 follow-up visits. We observed similar but nonsignificant decreased risks for HPV18 and 31. These findings were restricted to women reporting a new sex partner during follow-up. There was no association between baseline seroprevalence and detection of precancer during follow-up. CONCLUSIONS: Seroprevalence conferred protection against subsequent HPV infection for HPV16 and indicated possible protection for 2 other genotypes, suggesting that this effect is common to several HPV genotypes. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Natural human papillomavirus (HPV) antibody titers have shown protection against subsequent HPV infection, but previous studies were restricted to few HPV genotypes. We examined the association of naturally occurring antibodies against 8 carcinogenic HPV types with subsequent infections. METHODS: A total of 2302 women enrolled in the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study provided blood samples at baseline. Serum samples were tested for antibodies against 8 carcinogenic HPV genotypes (16, 18, 31, 33, 35, 45, 52, and 58) using a multiplex serology assay. We analyzed the relationship between HPV antibodies and HPV infection during 2 years of follow-up among women negative for the specific HPV type at baseline. RESULTS: Baseline seroprevalence for HPV16 L1 was associated with decreased risk of DNA positivity for HPV16 (odds ratio, 0.39 [95% confidence interval, .18-.86]) at ≥2 follow-up visits. We observed similar but nonsignificant decreased risks for HPV18 and 31. These findings were restricted to women reporting a new sex partner during follow-up. There was no association between baseline seroprevalence and detection of precancer during follow-up. CONCLUSIONS: Seroprevalence conferred protection against subsequent HPV infection for HPV16 and indicated possible protection for 2 other genotypes, suggesting that this effect is common to several HPV genotypes. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
Human papillomavirus; natural immunity; serology
Authors: P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple Journal: J Clin Microbiol Date: 2000-01 Impact factor: 5.948
Authors: C B Woodman; S Collins; H Winter; A Bailey; J Ellis; P Prior; M Yates; T P Rollason; L S Young Journal: Lancet Date: 2001-06-09 Impact factor: 79.321
Authors: Lauren E Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen Journal: Int J Cancer Date: 2013-05-29 Impact factor: 7.396
Authors: Philip E Castle; Mark Schiffman; Patti E Gravitt; Hortense Kendall; Stacy Fishman; Huali Dong; Allan Hildesheim; Rolando Herrero; M Concepcion Bratti; Mark E Sherman; Attila Lorincz; John E Schussler; Robert D Burk Journal: J Med Virol Date: 2002-11 Impact factor: 2.327
Authors: Raphael P Viscidi; Mark Schiffman; Allan Hildesheim; Rolando Herrero; Philip E Castle; Maria C Bratti; Ana Cecilia Rodriguez; Mark E Sherman; Sophia Wang; Barbara Clayman; Robert D Burk Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-02 Impact factor: 4.254
Authors: F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah Journal: J Natl Cancer Inst Date: 1995-06-07 Impact factor: 13.506
Authors: Gloria Y F Ho; Yevgeniy Studentsov; Charles B Hall; Robert Bierman; Leah Beardsley; Michele Lempa; Robert D Burk Journal: J Infect Dis Date: 2002-08-28 Impact factor: 5.226
Authors: S S Wang; M Schiffman; R Herrero; J Carreon; A Hildesheim; A C Rodriguez; M C Bratti; M E Sherman; J Morales; D Guillen; M Alfaro; B Clayman; R D Burk; R P Viscidi Journal: Br J Cancer Date: 2004-10-04 Impact factor: 7.640
Authors: Anil K Chaturvedi; Barry I Graubard; Tatevik Broutian; Robert K L Pickard; Zhen-Yue Tong; Weihong Xiao; Lisa Kahle; Maura L Gillison Journal: Cancer Res Date: 2015-04-14 Impact factor: 12.701
Authors: Hilary A Robbins; Tim Waterboer; Carolina Porras; Troy J Kemp; Michael Pawlita; Ana Cecilia Rodriguez; Sholom Wacholder; Paula Gonzalez; John T Schiller; Douglas R Lowy; Mark Esser; Katie Matys; Sylviane Poncelet; Rolando Herrero; Allan Hildesheim; Ligia A Pinto; Mahboobeh Safaeian Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452
Authors: Nadja Vielot; Michael G Hudgens; Nelly Mugo; Michael Chitwa; Joshua Kimani; Jennifer Smith Journal: Sex Transm Dis Date: 2015-06 Impact factor: 2.830
Authors: Sara L Bissett; Anna Godi; Maxime J J Fleury; Antoine Touze; Clementina Cocuzza; Simon Beddows Journal: J Virol Date: 2015-05-20 Impact factor: 5.103
Authors: Daniel C Beachler; Raphael Viscidi; Elizabeth A Sugar; Howard Minkoff; Howard D Strickler; Ross D Cranston; Dorothy J Wiley; Lisa P Jacobson; Kathleen M Weber; Joseph B Margolick; Susheel Reddy; Maura L Gillison; Gypsyamber D'Souza Journal: Sex Transm Dis Date: 2015-02 Impact factor: 2.830
Authors: Tsung-Chieh Jane Fu; Joseph J Carter; James P Hughes; Qinghua Feng; Stephen E Hawes; Stephen M Schwartz; Long Fu Xi; Taylor Lasof; Joshua E Stern; Denise A Galloway; Laura A Koutsky; Rachel L Winer Journal: Int J Cancer Date: 2016-08-04 Impact factor: 7.396
Authors: David P Durham; Martial L Ndeffo-Mbah; Laura A Skrip; Forrest K Jones; Chris T Bauch; Alison P Galvani Journal: Proc Natl Acad Sci U S A Date: 2016-04-18 Impact factor: 11.205